Table 2.
CSU Treatment | Mild COVID-19 Infection (n = 21) |
Moderate/Severe COVID-19 Infection (n = 51) |
---|---|---|
Single dose AH1 | 14.2% (3) | 1.9% (1) |
Double dose AH1 | 42.8% (9) | 29.4% (15) |
Four-fold dose AH1 | 33.3% (7) | 39.1% (20) |
Omalizumab | 0% (0) | 19.6% (10) |
Cyclosporine | 0% (0) | 0% (0) |
Prednisone | 0% (0) | 3.9% (2) |
No treatment | 9.7% (2) | 9.1% (5) |